Atlas Trials

MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC

Clinical trial NCT03418532 · TERMINATED

Trial details

NCT number
NCT03418532
Sponsor
Molecular Partners AG
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
EGFR-mutated NSCLC (Disorder)
Start date
2018-03-22
Primary completion
2019-08-30
Enrollment
8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.